DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

BNTX·BioNTech SE

$.
-. (-.%)
After Hours
High
$93.44
Open
$93.44
Market Cap
23.51B
52W High
$124.00
Low
$91.02
P. Close
$91.44
P/E
-
52W Low
$79.52
Fwd P/E
-18.08
DailyIQ Est.
$129.39
Technical Score (1D)
36
SELL
News Sentiment
51
MIXED
BioNTech’s valuation has come under scrutiny after a 57 % decline over the past five years, prompting investors to question whether the current price still reflects realistic upside. The company’s decision to exit certain German manufacturing sites could trim operating costs, but it also introduces execution risk that could delay or dilute those savings. Because the stock’s valuation score is low, many analysts believe the market has already priced in these operational changes, leaving little room for further upside. If the cost reductions materialize as planned, the company’s margin profile may improve, but the upside will likely remain modest. Conversely, any execution hiccups could trigger a sharper decline in the next 1–10 trading days. Traders should watch for updates on production capacity and cost metrics from the German sites, as these will clarify the speed and extent of the savings. Additionally, keep an eye on any new guidance regarding revenue growth or the product pipeline, which could shift the valuation narrative. A positive cost narrative could stabilize the stock, while negative news could spark a sell‑off. Broader biotech sentiment and regulatory developments will also influence the company’s valuation, so monitor those channels for potential catalysts.
Earnings Summary
BioNTech SE is a German biotechnology firm focused on developing and commercializing immunotherapies for cancer and infectious diseases, with a pipeline that spans multiple solid tumor indications such as melanoma, head and neck squamous cell carcinoma, and non‑small cell lung cancer. Operating within the highly competitive healthcare biotechnology sector, the company relies on clinical trial progress and regulatory approvals to drive its growth prospects. In the most recent reporting period, BioNTech reported Q4 2025 revenue of $907 million, down from $1.19 billion in Q4 2024, while its earnings per share improved from a negative $2.02 to a negative $0.33, reflecting a partial mitigation of losses as the company’s product pipeline advances. The following quarter, Q1 2026, saw revenue collapse to $118 million and EPS slide to a negative $1.95, indicating a sharp decline in sales momentum and a deterioration in profitability relative to the prior quarter. Over the last four quarters, the company has posted two earnings beats (Q4 2024 and Q4 2025) against analyst expectations, but missed in Q1 2026, underscoring a mixed performance pattern where revenue contraction has outpaced the modest improvement in earnings. Historically, BioNTech’s revenue trajectory has been volatile, with a steep decline from 2024 to 2025 and an even steeper drop into 2026, while EPS has remained negative, albeit with occasional improvements that have occasionally exceeded forecasts. Investors should watch for the next quarterly report to assess whether the company can reverse its revenue decline, sustain the EPS improvement trend, and provide clearer guidance on the commercialization timeline of its key candidates, as these factors will be critical in determining the company’s ability to regain investor confidence and support its valuation in the biotech space.

EPS

EstBeatMiss
$-2.84$-1.73$-0.62$0.48$1.59Q4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-2.33 - -
Q1'26$-2.29$-1.95+15.0%
Q4'25$-2.02$-0.33+83.9%
Q4'24$0.37$1.08+188.9%

Revenue

EstBeatMiss
$-43M$306M$654M$1.0B$1.4BQ4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$162M - -
Q1'26$249M$118M-52.5%
Q4'25$321M$907M+182.8%
Q4'24 - $1.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BNTX Stock Snapshot

BNTX is currently trading at $91.49, giving BioNTech SE a market cap of 23.51B. Today's range spans $91.02–$93.44, with shares opening at $93.44 and moving up $0.05 (0.1%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 51/100.

Over the past year BNTX has traded between $79.52 and $124.00 - the current price is +15.1% off the 52-week low and -26.2% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $121.95 (range $75.87–$154.48), implying upside of +33.3%.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, BNTX (36/100, HOLD, price $91.49, in the lower half of its 52-week range) is waiting for that resolution. Sentiment: neutral at 51/100. With 23.51B in market cap, the 52-week range of $79.52–$124.00 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

Portfolio construction in Healthcare often uses large-cap names like BNTX as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 36/100 (HOLD) at $91.49 (in the lower half of its 52-week range) and neutral sentiment (51/100) frame the position as a catalyst play within the $79.52–$124.00 annual range rather than a directional bet.